Latest / Glaucoma, Vision & Longevity: Supplements & Science / Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained

Transcript

Could Cataract Surgery Give You a Glaucoma Drug That Lasts for Years? The Bimatoprost-Releasing Lens Explained · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Could cataract surgery give you a glaucoma drug that lasts for years?
• 0:03
  SPEAKER_00: The Bimatoprost releasing lens explained, potentially, but not for everyone, and not as a cure for glaucoma.
• 0:10
  SPEAKER_00: Spyglass Pharma's investigational Bimatoprost Drug Pad Interocular Lens System, or BIM IOL, combines an artificial cataract lens with two small drug-releasing pads.
• 0:21
  SPEAKER_00: The lens is designed to release Bimatoprost, a pressure-lowering medicine, for about three years.
• 0:27
  SPEAKER_00: The early results are striking.
• 0:29
  SPEAKER_00: In a randomized trial, roughly 96 to 98% of evaluable patients who received the drug-releasing lens were not using additional pressure-lowering drops at 12 months.
• 0:40
  SPEAKER_00: A much smaller first-in-human study found that 20 of 21 participants followed for three years remained drop-free.
• 0:48
  SPEAKER_00: Those results make the idea worth taking seriously.
• 0:51
  SPEAKER_00: But drop-free is not the same as glaucoma-free, and the strongest three-year result comes from a small, uncontrolled study, not the larger randomized trial.
• 1:02
  SPEAKER_00: This article reviews the evidence available as of October 18, 2026, including the latest American Academy of Ophthalmology meeting presentation.
• 1:11
  SPEAKER_00: The BIM IOL remains investigational and not approved by the United States Food and Drug Administration.
• 1:17
  SPEAKER_00: AAO 2026 results coverage.
• 1:20
  SPEAKER_00: What is the spyglass bimatoprost drug pad intraocular lens?
• 1:24
  SPEAKER_00: During cataract surgery, the cloudy natural lens is removed and replaced with an intraocular lens.
• 1:31
  SPEAKER_00: The spyglass system uses a monofocal artificial lens with two bimatoprost containing pads attached near the junction between the lens's clear center and its supporting arms.
• 1:42
  SPEAKER_00: The lens and pads are placed inside the eye's capsular bag where the natural lens used to sit.
• 1:48
  SPEAKER_00: The pads are positioned outside the main visual area and are designed to release bimatoprost slowly.
• 1:54
  SPEAKER_00: Unlike an implant placed in the eye's drainage angle, the BIM IOL is intended to leave that angle available for future glaucoma procedures.
• 2:02
  SPEAKER_00: Adding the pads requires preparation of the lens but is intended to fit within a routine cataract surgery workflow.
• 2:09
  SPEAKER_00: Publish three-year pilot study.
• 2:12
  SPEAKER_00: The system is designed to deliver medication for three years.
• 2:16
  SPEAKER_00: That is a design goal supported by laboratory release testing and early human pressure measurements, not yet proof that every patient will receive three full years of effective treatment.
• 2:27
  SPEAKER_00: What did the AAO 2026 presentation report?
• 2:31
  SPEAKER_00: At the American Academy of Ophthalmology annual meeting in New Orleans, held October 9-12, 2026, investigator Fia Zaman presented 12-month results from Spyglass's randomized phase one-half trial.
• 2:45
  SPEAKER_00: The trial enrolled people with a cataract and either mild to moderate open-angle glaucoma or ocular hypertension.
• 2:52
  SPEAKER_00: AAO 2026 presentation coverage, trial groups and pressure results.
• 2:58
  SPEAKER_00: A total of 104 people were randomized.
• 3:01
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 3:05
  SPEAKER_00: All participants stopped their existing pressure lowering treatment for a washout period before the baseline measurements.
• 3:12
  SPEAKER_00: The exact group mean washout pressures were not included in the public AAO report I could verify.
• 3:18
  SPEAKER_00: Dividing the reported pressure reductions by the rounded percentages gives an approximate baseline of about 25 to 27 mmHAS, depending on group and measurement time.
• 3:29
  SPEAKER_00: These are calculated estimates, not separately published baseline figures.
• 3:34
  SPEAKER_00: AAO 2026 results report the lower dose group had a numerically larger reduction than the higher dose group.
• 3:41
  SPEAKER_00: That does not establish that 39 micrograms is better.
• 3:45
  SPEAKER_00: These reported averages do not demonstrate a clear dose response relationship, and the small groups are not a definitive dose comparison.
• 3:54
  SPEAKER_00: How many patients were off pressure lowering drops?
• 3:57
  SPEAKER_00: At 12 months, the presentation reported that 98% of patients in the 78 microgram group were off additional pressure lowering medication.
• 4:06
  SPEAKER_00: 96% of patients in the 39 microgram group were off additional pressure lowering medication.
• 4:12
  SPEAKER_00: Control group participants were not reported as drop-free in the same sense.
• 4:17
  SPEAKER_00: They were still using their assigned twice-daily timelol.
• 4:21
  SPEAKER_00: The company has summarized the combined treated groups as approximately 97% off-topical pressure lowering therapy at 12 months.
• 4:30
  SPEAKER_00: Medication-free here means free of additional pressure-lowering eye drops.
• 4:35
  SPEAKER_00: Patients in the BIM IOL groups used artificial tears as part of the trial and still received ordinary postoperative eye care.
• 4:42
  SPEAKER_00: AAO 2026 report and spyglass phase one results.
• 4:46
  SPEAKER_00: Vision, corneal cells, and adverse events.
• 4:49
  SPEAKER_00: The reported visual outcomes were reassuring.
• 4:52
  SPEAKER_00: All evaluable eyes in all three groups achieved best corrected distance vision of 2032 or better.
• 4:59
  SPEAKER_00: Vision of 2020 or better was reported in 74% of the 78 microgram group, 65% of the 39 microgram group, and 63% of the control group.
• 5:10
  SPEAKER_00: Average vision across groups was about 86 letters, roughly equivalent to 2020 vision.
• 5:16
  SPEAKER_00: The presentation also reported corneal endothelial cell density, a measure of the health of the cells lining the inside of the cornea.
• 5:25
  SPEAKER_00: For the full table, please open this article on visualfieldtest.com.
• 5:29
  SPEAKER_00: The investigators characterize the overall safety profile and endothelial cell loss as comparable to routine cataract surgery.
• 5:38
  SPEAKER_00: However, the numerically larger decline in the smaller 39 microgram group deserves follow-up.
• 5:45
  SPEAKER_00: These are calculations from reported group averages.
• 5:48
  SPEAKER_00: The public conference coverage does not provide a full adjusted comparison or enough detail to interpret the differences confidently.
• 5:55
  SPEAKER_00: AAO 2026 Safety and Vision Results.
• 5:58
  SPEAKER_00: Any adverse event was reported in 21 people in the 78 microgram group, 41%, 10 in the 39 microgram group, 43%, and 11 in the control group, 37%.
• 6:11
  SPEAKER_00: The report described no serious adverse events, secondary surgical interventions, or lens explantations through 12 months.
• 6:19
  SPEAKER_00: The public report does not provide a complete event-by-event breakdown, so the overall percentages should not be read as the proportion who had a problem caused by the drug pads.
• 6:30
  SPEAKER_00: How meaningful is a 96 to 98% drop-free result?
• 6:34
  SPEAKER_00: It is a meaningful early signal.
• 6:37
  SPEAKER_00: If confirmed in larger and longer studies, avoiding daily pressure-lowering drops could reduce the burden of remembering, handling, and paying for them.
• 6:45
  SPEAKER_00: That could matter especially for people who struggle with daily dosing.
• 6:49
  SPEAKER_00: But the headline needs context.
• 6:51
  SPEAKER_00: It does not mean 98% of patients stopped drops they were taking nowhere.
• 6:56
  SPEAKER_00: About one-third of trial participants were taking no pressure-lowering medication at screening.
• 7:02
  SPEAKER_00: They may have had elevated pressure without current treatment, or they may have been suitable for observation under their clinician's care.
• 7:10
  SPEAKER_00: So the reported drop-free percentage is not the same as saying that 96 to 98% of people who had been using drops successfully stopped them after surgery.
• 7:20
  SPEAKER_00: The report does not provide enough detail to calculate that specific number.
• 7:24
  SPEAKER_00: AAO 2026 study details.
• 7:28
  SPEAKER_00: The control group also had a large pressure reduction.
• 7:32
  SPEAKER_00: The control group had ordinary cataract surgery, received a standard lens, and used timolol.
• 7:38
  SPEAKER_00: Its reported pressure reduction, about 35% at 12 months, was close to the reductions in the drug pad groups.
• 7:44
  SPEAKER_00: This trial therefore supports the idea that the BIM IOL can maintain pressure control while avoiding assigned TMALOL drops.
• 7:52
  SPEAKER_00: It does not show that the BIM IOL lowered pressure more than the control treatment.
• 7:57
  SPEAKER_00: Cataract surgery itself can lower pressure, especially when the starting pressure is high.
• 8:03
  SPEAKER_00: Estimates differ depending on the patients studied and whether pressure-lowering medications were stopped before measurement.
• 8:10
  SPEAKER_00: A 2024 review of cataract surgery trials found a 12-month average reduction of about 3.8 millimeter grams overall, with a larger average reduction in studies that used a medication washout.
• 8:22
  SPEAKER_00: Cataract surgery meta-analysis.
• 8:25
  SPEAKER_00: Drop-free is not the same as glaucoma controlled for life.
• 8:28
  SPEAKER_00: The phase one-half trial reported eye pressure, vision, medication use, and safety.
• 8:34
  SPEAKER_00: It did not establish that the lens prevents future visual field loss, stops optic nerve damage, or removes the need for future glaucoma care.
• 8:43
  SPEAKER_00: The 12-month results are also interim data presented at a medical meeting.
• 8:48
  SPEAKER_00: The available report is not a full peer-reviewed paper with all trial details.
• 8:53
  SPEAKER_00: Bottom line, the result is promising evidence of a strong chance of being free from additional pressure-lowering drops at one year in this selected study group.
• 9:03
  SPEAKER_00: It is not yet proof that most people having cataract surgery can avoid glaucoma treatment indefinitely.
• 9:10
  SPEAKER_00: Does the pressure lowering effect really last three years?
• 9:14
  SPEAKER_00: The most direct human evidence comes from a small, prospective, non-randomized first-in-human study in Honduras.
• 9:21
  SPEAKER_00: The published paper says 24 people consented.
• 9:24
  SPEAKER_00: Company materials have described 23 people assigned to dose groups.
• 9:28
  SPEAKER_00: 21 were followed through 36 months.
• 9:31
  SPEAKER_00: The study tested older configurations containing 75, 150, or 300 micrograms of bimatoprost, not the 39 and 78 microgram doses in the later randomized trial.
• 9:42
  SPEAKER_00: Published three-year pilot study and company 36-month results.
• 9:46
  SPEAKER_00: At 36 months, the reported average pressure for evaluable participants had fallen from 25.12.5 mmhergrams after washout to 15.9-2.7 mm, a reduction of about 37%.
• 10:00
  SPEAKER_00: 20 of 21 participants were still free of topical pressure lowering medication.
• 10:06
  SPEAKER_00: All 21 had at least a 20% pressure reduction from baseline, and 19 of 21 had pressure below 18 mmHH drams at their final visit.
• 10:16
  SPEAKER_00: One participant in the highest dose group restarted a pressure lowering medication at month 30.
• 10:22
  SPEAKER_00: The researchers reported that pressure lowering was broadly maintained through three years.
• 10:28
  SPEAKER_00: There was a small pressure uptick in the 150 microgram group during year three, but not a similar pattern in the 75 microgram group.
• 10:37
  SPEAKER_00: The paper's authors suggested that the increase could reflect the variability of small groups rather than waning drug effect.
• 10:44
  SPEAKER_00: The study cannot settle that question.
• 10:47
  SPEAKER_00: Three-year study.
• 10:48
  SPEAKER_00: This supports three-year clinical pressure control in a very small selected group.
• 10:54
  SPEAKER_00: It does not prove that drug release itself remained perfectly constant inside each eye.
• 10:59
  SPEAKER_00: No published patient-level drug release measurement shows exactly how much medicine was being released over time.
• 11:06
  SPEAKER_00: Laboratory testing is reported to show sustained release for more than three years, while the human study offers an indirect clinical measure, eye pressure.
• 11:16
  SPEAKER_00: The first inhuman study also selected participants who had previously responded to prostaglandin medicines, such as bimataprost.
• 11:25
  SPEAKER_00: It had no cataract surgery-only control group, no randomization, and no masking.
• 11:32
  SPEAKER_00: The authors themselves noted that cataract surgery can lower pressure and that the study was not designed to establish how the system would perform in more difficult-to-control glaucoma.
• 11:42
  SPEAKER_00: Spyglass said in August 2026 that four-year follow-up results were expected in the fourth quarter of 2026.
• 11:50
  SPEAKER_00: Those results were not yet available by October 18, 2026.
• 11:55
  SPEAKER_00: Spyglass second quarter 2026 update.
• 11:58
  SPEAKER_00: What happens when the drug runs out?
• 12:01
  SPEAKER_00: The drug pads are designed to be non-bioerotable.
• 12:04
  SPEAKER_00: They do not dissolve as the medicine is released.
• 12:07
  SPEAKER_00: Once their medication is depleted, the pads are intended to remain attached to the lens inside the capsular bag.
• 12:13
  SPEAKER_00: Spyglass Company filing.
• 12:15
  SPEAKER_00: Can the pads be replaced?
• 12:16
  SPEAKER_00: There is no established procedure to replace just the pads inside the eye.
• 12:21
  SPEAKER_00: They are attached to the lens.
• 12:23
  SPEAKER_00: Can other glaucoma treatment be added?
• 12:26
  SPEAKER_00: In principle, a clinician could consider pressure lowering drops, laser treatment, or surgery if pressure rises.
• 12:33
  SPEAKER_00: Using another sustained release implant after BIM IOL has not been established in clinical studies, and the choice would depend on the person's eye and the other product's instructions.
• 12:43
  SPEAKER_00: Can conventional drops be restarted?
• 12:45
  SPEAKER_00: Yes.
• 12:46
  SPEAKER_00: A lens that has stopped releasing enough medicine does not prevent a doctor from prescribing drops again.
• 12:52
  SPEAKER_00: Can selective laser treatment or glaucoma surgery still be done?
• 12:56
  SPEAKER_00: The pads sit in the capsular bag rather than the drainage angle.
• 13:00
  SPEAKER_00: That is intended to preserve the angle for future treatment.
• 13:03
  SPEAKER_00: However, there are not yet large clinical series testing every possible sequence of BIM IOL followed by a glaucoma procedure.
• 13:12
  SPEAKER_00: Would the whole lens need replacing when the pads are empty?
• 13:16
  SPEAKER_00: Not as a planned part of routine treatment.
• 13:19
  SPEAKER_00: Replacing an artificial lens is a separate operation with its own risks, not a standard way to reload the BIM IOL.
• 13:26
  SPEAKER_00: The lens would generally stay in place unless there were another clinical reason to exchange it.
• 13:32
  SPEAKER_00: Spyglass is also developing a separate Bimataprost drug ring system, designed to be removable and replaceable for people who already have an artificial lens.
• 13:42
  SPEAKER_00: It remains investigational.
• 13:44
  SPEAKER_00: It is not an approved or proven way to retreat patients whose BIM IL pads have run out.
• 13:48
  SPEAKER_00: Spyglass Company filing.
• 13:51
  SPEAKER_00: How does BIM IL compare with other glaucoma treatments?
• 13:54
  SPEAKER_00: These figures come from different trials and different patient groups.
• 13:58
  SPEAKER_00: Except for the BIM IOL trials comparison with TMALOL, they are not head-to-head comparisons.
• 14:05
  SPEAKER_00: Starting pressure, medication washout, disease severity, and follow-up time all affect the results.
• 14:11
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 14:15
  SPEAKER_00: Sources: First Line Glaucoma Medicine Review, IDOSE TR United States Label, Derista United States Label, Light Six Year Results, American Academy of Ophthalmology Cataractin Glaucoma Guidance, and Five-Year Hydrus Trial.
• 14:29
  SPEAKER_00: The comparison makes an important point.
• 14:31
  SPEAKER_00: The roughly 35% pressure reduction in the BIM IOL trial does not establish superiority over ordinary treatment.
• 14:38
  SPEAKER_00: Its clearest potential advantage is that many participants did not need additional pressure lowering drops while achieving pressure reductions similar to the Timolol plus cataract surgery control group.
• 14:51
  SPEAKER_00: Does a permanent drug pad create long-term risks?
• 14:55
  SPEAKER_00: So far, the small human studies have not revealed a clear mechanical or vision problem, but three years in a small group is not the same as proving lifetime safety for a device that may remain in an eye for decades.
• 15:08
  SPEAKER_00: Corneal endothelial cells.
• 15:10
  SPEAKER_00: In the randomized study, the reported 12-month endothelial cell results were described as comparable overall to routine cataract surgery.
• 15:18
  SPEAKER_00: In the three-year pilot, cell density was measured at 6 and 12 months, not at 36 months.
• 15:24
  SPEAKER_00: The authors also noted that the counts were not confirmed by a formal reading center.
• 15:29
  SPEAKER_00: This leaves a significant gap in the evidence about long-term corneal cell health.
• 15:35
  SPEAKER_00: Inflammation, scarring, and drug crystallization.
• 15:38
  SPEAKER_00: The first in-human study reported unremarkable postoperative inflammation and no serious implant-related adverse events.
• 15:46
  SPEAKER_00: It did not report drug crystallization, but the small study was not large enough to rule out rare events.
• 15:52
  SPEAKER_00: Long-term scarring or fibrosis around the pads has not been established as a clinical problem, but it also has not been adequately ruled out over a patient's lifetime.
• 16:03
  SPEAKER_00: Bermatoprost belongs to a class of medicines that can be associated with inflammation or macular swelling in some settings.
• 16:11
  SPEAKER_00: No such serious implant-related signal was reported in the small spyglass studies, but established warnings for bimatoprost-containing treatments are a reason to continue monitoring rather than assume that a sustained release version has no class-related risk.
• 16:26
  SPEAKER_00: Darista United States label.
• 16:28
  SPEAKER_00: Lens stability and visual quality.
• 16:31
  SPEAKER_00: In the three-year pilot, the researchers reported no lens dislocations, pad displacements, or explantations.
• 16:38
  SPEAKER_00: All study eyes had best corrected vision of 2030 or better at final follow-up.
• 16:44
  SPEAKER_00: The study reported no clinically significant posterior capsule opacification, a clouding that can sometimes develop behind an artificial lens.
• 16:52
  SPEAKER_00: Those findings are reassuring but preliminary.
• 16:55
  SPEAKER_00: They do not answer every question about lens optics, uncommon mechanical problems, or what happens after procedures such as laser treatment for posterior capsule clouding.
• 17:06
  SPEAKER_00: The early clinical work used a monofocal lens.
• 17:09
  SPEAKER_00: Claims that the pad system may work with other lens designs are not the same as clinical evidence for those designs.
• 17:16
  SPEAKER_00: Future retinal or glaucoma surgery.
• 17:19
  SPEAKER_00: Because the BIM IOL is placed in the capsular bag and not in the eye's drainage angle, it is not intended to block the angle used for many glaucoma treatments.
• 17:28
  SPEAKER_00: That makes future laser treatment, angle surgery, or other glaucoma surgery anatomically plausible.
• 17:34
  SPEAKER_00: But the claim that it preserves options is based mainly on where the lens sits.
• 17:39
  SPEAKER_00: Dedicated studies of later procedures in BIM IOL eyes are still needed.
• 17:44
  SPEAKER_00: The early studies likewise do not establish how the pads affect every future retinal operation.
• 17:50
  SPEAKER_00: Their location outside the main visual axis and inside the capsular bag suggests that they should not automatically prevent retinal surgery, but there is not yet a large body of clinical experience to confirm all possible surgical scenarios.
• 18:04
  SPEAKER_00: Spyglass BIM IOL versus IDOSTR, which is the better long-term idea?
• 18:09
  SPEAKER_00: They solve different problems.
• 18:11
  SPEAKER_00: BIM IOL is designed to make the cataract operation itself carry several years of medication delivery.
• 18:17
  SPEAKER_00: It avoids a separate drainage angle implant procedure and is intended to leave the angle available.
• 18:23
  SPEAKER_00: The trade-off is that the pads cannot be exchanged independently of the artificial lens.
• 18:29
  SPEAKER_00: IDOSTR is a separate implant placed in the drainage angle.
• 18:33
  SPEAKER_00: Its January 2026 United States label includes a method to remove the old implant after placing a new one, subject to corneal cell assessment and other precautions.
• 18:43
  SPEAKER_00: Readministration is not recommended more than once per year.
• 18:47
  SPEAKER_00: That makes it more adjustable and retreatable in principle, but retreatment involves another procedure and removal of the prior implant.
• 18:55
  SPEAKER_00: IDOS TR United States label.
• 18:58
  SPEAKER_00: For the full table, please open this article on VisualFieldTest.com.
• 19:02
  SPEAKER_00: Which is the better long-term idea?
• 19:05
  SPEAKER_00: For someone already having cataract surgery who wants to avoid a separate glaucoma procedure, the BIM IOL concept is attractive, if its longer-term safety and effectiveness are confirmed.
• 19:15
  SPEAKER_00: For a person who values the ability to replace or repeat the drug source, IDOSTR has the more flexible design, though it requires angle surgery and has its own placement, removal, and endothelial cell considerations.
• 19:28
  SPEAKER_00: There is no head-to-head trial establishing one as better overall.
• 19:33
  SPEAKER_00: Spyglass says a dedicated add-on billing code was approved in 2026 and anticipates a physician-administered drug reimbursement pathway if the product is approved.
• 19:43
  SPEAKER_00: Those are company expectations, not a final guarantee of coverage or a known patient price.
• 19:49
  SPEAKER_00: The company has not published a BIM IOL price or cost effectiveness analysis.
• 19:54
  SPEAKER_00: Spyglass second quarter 2026 update and company filing.
• 19:59
  SPEAKER_00: What is happening in phase 3 and when could it reach patients?
• 20:03
  SPEAKER_00: SpyGlass is running two registrational phase 3 trials, SGP 005 and SGP006.
• 20:10
  SPEAKER_00: The trials are designed to enroll about 400 participants each.
• 20:14
  SPEAKER_00: They compare the 78 microgram BIM IOL with a standard lens plus twice daily time al.
• 20:20
  SPEAKER_00: The co-primary outcomes include pressure change and the proportion of patients achieving best corrected distance vision of 2040 or better.
• 20:28
  SPEAKER_00: Participants are expected to be followed for up to 36 months.
• 20:33
  SPEAKER_00: Phase 3 trial announcement.
• 20:35
  SPEAKER_00: Spyglass reported in August 2026 that enrollment remained on track for completion in 2027.
• 20:42
  SPEAKER_00: The company has said it plans to submit a new drug application to the United States Food and Drug Administration in 2028 if the Phase 3 results support it.
• 20:52
  SPEAKER_00: A possible approval in 2029 or later is therefore conceivable, but not promised.
• 20:58
  SPEAKER_00: Recruitment delays, trial results, the regulator's review, or a request for additional durability or safety evidence could shift the timeline.
• 21:07
  SPEAKER_00: Spyglass August 2026 update and company filing, a cautious estimate of the chances.
• 21:13
  SPEAKER_00: The following are judgment estimates, not published statistical forecasts.
• 21:18
  SPEAKER_00: Chance both phase three trials meet their short-term primary endpoints, roughly 65 to 75%.
• 21:25
  SPEAKER_00: The randomized phase one half pressure results and vision data are encouraging, but the pivotal trials must reproduce them in a larger population, and both trials must meet their targets.
• 21:36
  SPEAKER_00: Chance of eventual United States approval from the current stage, roughly 50 to 60%.
• 21:41
  SPEAKER_00: Approval depends on more than a short-term pressure result.
• 21:45
  SPEAKER_00: The regulator will also assess the combined drug and lens product, safety, vision, manufacturing, and the adequacy of follow-up.
• 21:53
  SPEAKER_00: Likely medication-free share at three years in patients similar to the study population, a cautious estimate is about 75 to 90%.
• 22:02
  SPEAKER_00: The small first-in-human study reported 20 of 21 off drops at three years, but that result has not yet been reproduced at scale with the intended 78 microgram dose.
• 22:13
  SPEAKER_00: Likely share needing additional pressure-lowering treatment by three years, perhaps 10 to 25%, depending on disease severity and how strict a person's pressure target is.
• 22:24
  SPEAKER_00: This estimate is uncertain and includes people who may need drops or another procedure.
• 22:30
  SPEAKER_00: The last two estimates are not trial findings.
• 22:33
  SPEAKER_00: They extrapolate from small, selected studies and should not be used to predict an individual patient's outcome.
• 22:40
  SPEAKER_00: Which patients might benefit most?
• 22:43
  SPEAKER_00: If later studies support the early results, the most plausible candidates would be people who need cataract surgery anyway, have ocular hypertension, or mild to moderate open-angle glaucoma, have a pressure target that can reasonably be met with one pressure-lowering medicine, have previously responded to prostaglandin treatment, want to reduce the burden of daily glaucoma drops.
• 23:06
  SPEAKER_00: The early evidence does not establish BIM IOL as a standalone answer for advanced glaucoma, rapid disease progression, or people who need very low pressure targets.
• 23:16
  SPEAKER_00: Those patients may need more intensive treatment.
• 23:19
  SPEAKER_00: The three-year pilot also selected people who had responded to prostaglandin medicines, which limits how well its results may apply to people who do not respond.
• 23:30
  SPEAKER_00: Could cataract surgery become a one-time treatment for both cataract and glaucoma?
• 23:35
  SPEAKER_00: It could become a one-time cataract procedure that provides years of pressure-lowering medicine for some people.
• 23:41
  SPEAKER_00: It is not a one-time cure for glaucoma.
• 23:44
  SPEAKER_00: The strongest early promise is freedom from daily pressure-lowering drops, not freedom from glaucoma treatment or follow-up.
• 23:52
  SPEAKER_00: The drug supply is finite.
• 23:54
  SPEAKER_00: Some people may need drops or another procedure before or after it runs out, and pressure control does not reverse existing optic nerve damage.
• 24:03
  SPEAKER_00: People with glaucoma still need ongoing checks of eye pressure, optic nerve health, and vision.
• 24:10
  SPEAKER_00: The BIM IOL could eventually make treatment easier for a subset of people who are already having cataract surgery, but it cannot yet be considered a replacement for long-term glaucoma monitoring.
• 24:21
  SPEAKER_00: American Academy of Ophthalmology Guidance on Open Angle Glaucoma.
• 24:26
  SPEAKER_00: All links to sources are available in the text version of this article.
• 24:30
  SPEAKER_00: You can find the full article at VisualFieldtest.com.
• 24:34
  SPEAKER_00: Thanks for listening.
• 24:35
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.